Merus N.V. (MRUS)
NASDAQ: MRUS · Real-Time Price · USD
96.82
-0.11 (-0.11%)
At close: Dec 15, 2025, 4:00 PM EST
96.84
+0.02 (0.02%)
After-hours: Dec 15, 2025, 5:25 PM EST
Merus Revenue
Merus had revenue of $12.15M in the quarter ending September 30, 2025, with 3.21% growth. This brings the company's revenue in the last twelve months to $56.61M, up 57.54% year-over-year. In the year 2024, Merus had annual revenue of $33.35M, down -17.97%.
Revenue (ttm)
$56.61M
Revenue Growth
+57.54%
P/S Ratio
121.73
Revenue / Employee
$176,343
Employees
321
Market Cap
7.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 33.35M | -7.30M | -17.97% |
| Dec 31, 2023 | 40.65M | -932.00K | -2.24% |
| Dec 31, 2022 | 41.59M | -7.52M | -15.32% |
| Dec 31, 2021 | 49.11M | 19.16M | 64.00% |
| Dec 31, 2020 | 29.94M | -1.19M | -3.82% |
| Dec 31, 2019 | 31.13M | -5.71M | -15.50% |
| Dec 31, 2018 | 36.84M | 10.55M | 40.10% |
| Dec 31, 2017 | 26.30M | 23.65M | 895.69% |
| Dec 31, 2016 | 2.64M | 494.31K | 23.03% |
| Dec 31, 2015 | 2.15M | 570.11K | 36.16% |
| Dec 31, 2014 | 1.58M | 809.22K | 105.46% |
| Dec 31, 2013 | 767.34K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
MRUS News
- 3 days ago - Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period - Business Wire
- 20 days ago - Bicara Therapeutics: Intriguing Opportunity Given Rival Merus' $8B Buyout - Seeking Alpha
- 4 weeks ago - Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab - PRNewsWire
- 6 weeks ago - 3 Investable Laggards In An Overbought Market - Seeking Alpha
- 7 weeks ago - Merus' Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety - GlobeNewsWire
- 7 weeks ago - Merus Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS - Business Wire
- 7 weeks ago - Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V. - GlobeNewsWire
- 2 months ago - Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire